PT Hetzer Medical Indonesia Tbk

meds

Overview

MEDS Overview

PT Hetzer Medical Indonesia Tbk is an Indonesia-based company, which is engaged in manufacturing and distributing masks for everyday use. The Company also produces and distributes hand sanitizers. It manufactures masks using an advanced technology. It distributes its products under Evo Plusmed brand. Evo Plusmed manufactures masks with four-dimensional (4D) designs in Indonesia. The Company's products include Evo Surgical Mask 3 Ply, Evo Plusmed 4D Color Edition, Evo Plusmed 4D Super Edition, Evo Plusmed 4D Special Edition, Evo Plusmed 4D Mask 5 Ply, Evo Mask Hijab Series, Evo Mask For Kids, Evo Antiseptic Handrub and Evo Plusmed Spark Edition. The Company's factory is located in Cimahi Bandung.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: MEDS

Development
Market Cap.
IDR 78.12Billion

~$4.93M USD

Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies & Distributions
Sector
Healthcare

Valuation

MEDS Valuation Metrics

50

IDR

Closing Price on 2024-04-05

Price to Equity

-8.05

P/E

At -8.05x P/E TTM, MEDS.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Price to Book

1.26

P/B

At 1.26x P/B TTM, MEDS.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Price to Sales

4.26

P/S

At 4.26x P/S TTM, MEDS.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 3.0x).

Valuing PT Hetzer Medical Indonesia Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Hetzer Medical Indonesia Tbk relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
13.22x
Price/Forward Earnings
-
Enterprise Value/Revenue
4.72x
Enterprise Value/EBITDA
-24.97x
PEG Ratio
0.14x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR502024-04-05
IDR 11.42

Considerably Lower Intrinsic Value: Analyst's intrinsic value is of MEDS is IDR11, which is 76% lower than MEDS's last closing price of IDR50 (as of 2024-04-05).

Valuation Recap of MEDS stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -8.05x is below the ID market average of 8.22x and is trading at a discount to peers in the Healthcare Equipment & Providers sector (23.78x). ●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.26x is below the peers average of 1.80x in the Healthcare Equipment & Providers sector. In fact, less than 25% of its peers trade at a lower P/B ratio than MEDS.●●
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 4.26x is above the peers average of 3.00x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of MEDS's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. MEDS's P/CF ratio of 13.22x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. MEDS's EV/R ratio of 4.72x is considered a relatively high ratio The average EV/R ratio for the Healthcare Equipment & Providers sector is 2.98x.
Max 3
Medium
Considerably Lower Intrinsic Value: Analyst's intrinsic value is of MEDS is IDR 11.42, which is 76% lower than MEDS's last closing price of IDR 50.00.
Max 3

Peers

MEDS Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of MEDS stock
WeightNotesScore
High
At a market cap of IDR 78.12 billion, MEDS.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -8.05, MEDS.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -20.86 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -8.05, MEDS.JK is trading at a lower PE than that of its subsector peers in Healthcare Equipment & Providers (median of 23.78). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 0.02 trillion, MEDS.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.01 trillion, MEDS.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of MEDS

Growth Forecasts

No data available

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 23.68% against the IDX average of +12.0%.

Healthcare Equipment & Providers sector overview
No data is available for MEDS at the moment.
Future growth prospect of MEDS
WeightNotesScore
High
MEDS's projected growth rate of 23.68% is above the ID market average of 11.98%.●●●
Max 3
High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 22.97% in 2024. This number is higher than the previous year 2023's growth rate of 9.96%. This bodes well for MEDS's revenue growth prospects in the next 2 years. ●●●
Max 3
Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 29.75% in 2024. This number is higher than the previous year 2023's EPS growth of 9.77%. This bodes well for MEDS's earnings growth prospects in the next 2 years. ●●●
Max 3
Medium
MEDS and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for MEDS's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

A. Padmono Budi Sanyoto15.2 years
Herry
Director
Fancy Marsiana, Sh
Director
NamePositionShares%
A. Padmono Budi SanyotoPresident Director62,500,0004
Fancy MarsianaDirector62,500,0004
Franciscus RijadiCommissioner437,500,00028
HerryDirector1,716,1000.11
Jemmy KurniawanPresident Commissioner562,500,00036
Expressed in millions IDR, unless otherwise stated

Ownership

MEDS Ownership

Others
23.89%
Insiders
76.11%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Jemmy Kurniawan562,500,0003628.13B
Franciscus Rijadi437,500,0002821.88B
Public (Scripless)435,783,90027.8921.79B
A. Padmono Budi Sanyoto62,500,00043.13B
Fancy Marsiana62,500,00043.13B
Herry1,716,1000.110.09B
No data is available for MEDS at the moment.